Shanghai INT Medical Instruments Future Growth
Future criteria checks 3/6
Shanghai INT Medical Instruments is forecast to grow earnings and revenue by 14.8% and 16.4% per annum respectively. EPS is expected to grow by 12.9% per annum. Return on equity is forecast to be 11.7% in 3 years.
Key information
14.8%
Earnings growth rate
12.9%
EPS growth rate
| Medical Equipment earnings growth | 42.4% |
| Revenue growth rate | 16.4% |
| Future return on equity | 11.7% |
| Analyst coverage | Low |
| Last updated | 20 Mar 2025 |
Recent future growth updates
No updates
Recent updates
Be Wary Of Shanghai Kindly Medical Instruments (HKG:1501) And Its Returns On Capital
Jul 14
Shanghai Kindly Medical Instruments' (HKG:1501) Shareholders Will Receive A Smaller Dividend Than Last Year
May 17Returns On Capital At Shanghai Kindly Medical Instruments (HKG:1501) Paint A Concerning Picture
Nov 26Shanghai Kindly Medical Instruments (HKG:1501) Is Reinvesting At Lower Rates Of Return
Aug 16Some Investors May Be Worried About Shanghai Kindly Medical Instruments' (HKG:1501) Returns On Capital
Apr 24Shareholders Are Loving Shanghai Kindly Medical Instruments Co., Ltd.'s (HKG:1501) 1.0% Yield
Apr 05What Is The Ownership Structure Like For Shanghai Kindly Medical Instruments Co., Ltd. (HKG:1501)?
Mar 15Declining Stock and Decent Financials: Is The Market Wrong About Shanghai Kindly Medical Instruments Co., Ltd. (HKG:1501)?
Jan 28Here's Why I Think Shanghai Kindly Medical Instruments (HKG:1501) Might Deserve Your Attention Today
Dec 28
Is Shanghai Kindly Medical Instruments Co., Ltd. (HKG:1501) Popular Amongst Insiders?
Dec 02Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 1,398 | 280 | 248 | 345 | 1 |
| 12/31/2026 | 1,225 | 245 | 209 | 308 | 1 |
| 12/31/2025 | 1,025 | 206 | 190 | 286 | 1 |
| 12/31/2024 | 852 | 181 | 60 | 226 | N/A |
| 9/30/2024 | 829 | 174 | 43 | 221 | N/A |
| 6/30/2024 | 805 | 167 | 27 | 217 | N/A |
| 3/31/2024 | 779 | 160 | -13 | 197 | N/A |
| 12/31/2023 | 753 | 152 | -53 | 178 | N/A |
| 9/30/2023 | 727 | 155 | -101 | 175 | N/A |
| 6/30/2023 | 700 | 159 | -149 | 172 | N/A |
| 3/31/2023 | 643 | 144 | -128 | 176 | N/A |
| 12/31/2022 | 586 | 130 | -108 | 180 | N/A |
| 9/30/2022 | 548 | 137 | -119 | 152 | N/A |
| 6/30/2022 | 509 | 143 | -129 | 124 | N/A |
| 3/31/2022 | 487 | 143 | -180 | 98 | N/A |
| 12/31/2021 | 465 | 143 | -230 | 73 | N/A |
| 9/30/2021 | 416 | 124 | -183 | 73 | N/A |
| 6/30/2021 | 367 | 105 | -135 | 73 | N/A |
| 3/31/2021 | 363 | 113 | -65 | 84 | N/A |
| 12/31/2020 | 358 | 121 | 6 | 96 | N/A |
| 9/30/2020 | 341 | 121 | N/A | N/A | N/A |
| 6/30/2020 | 323 | 120 | N/A | N/A | N/A |
| 3/31/2020 | 305 | 110 | N/A | N/A | N/A |
| 12/31/2019 | 286 | 100 | 18 | 92 | N/A |
| 12/31/2018 | 203 | 58 | 21 | 66 | N/A |
| 12/31/2017 | 138 | 41 | N/A | 39 | N/A |
| 12/31/2016 | 106 | 34 | N/A | 39 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1501's forecast earnings growth (14.8% per year) is above the savings rate (2.4%).
Earnings vs Market: 1501's earnings (14.8% per year) are forecast to grow faster than the Hong Kong market (10.5% per year).
High Growth Earnings: 1501's earnings are forecast to grow, but not significantly.
Revenue vs Market: 1501's revenue (16.4% per year) is forecast to grow faster than the Hong Kong market (8.1% per year).
High Growth Revenue: 1501's revenue (16.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1501's Return on Equity is forecast to be low in 3 years time (11.7%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/24 00:31 |
| End of Day Share Price | 2025/04/24 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shanghai INT Medical Instruments Co., Ltd. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | CMB International Securities Limited |
| Yu Wu | CMB International Securities Limited |
| Xin Qiu Lin | Guoyuan Securities (HK) Ltd |